title: [Molecular and genetic aspects of triple negative breast cancer and therapeutic implications].
abstract: Triple negative breast cancers are defined by the lack of expression of estrogen, progesterone and HER2 receptors. They represent an heterogeneous population with poor prognosis. The treatment of these tumors is a challenge because there is no known specific target. A huge number of studies try to better characterise these tumors at the molecular level with the aim to identify new therapeutic targets. The finding of new specific biomarkers like intracellular and extracellular microRNAs is also an important field of research. This article reviews some recent data in this field and the research on different pathways for the development of new therapies.
authors.affiliation: Service d'Oncologie Médicale, CHU de Liège, Belgique. joelle.collignon@chu.ulg.ac.be
authors.forename: J
authors.initials: J
authors.lastname: Collignon
authors.forename: I
authors.initials: I
authors.lastname: Struman
authors.forename: S
authors.initials: S
authors.lastname: Tabruyn
authors.forename: C
authors.initials: C
authors.lastname: Josse
authors.forename: M
authors.initials: M
authors.lastname: Boukerroucha
authors.forename: G
authors.initials: G
authors.lastname: Jerusalem
authors.forename: V
authors.initials: V
authors.lastname: Bours
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology*; D019175:DNA Methylation; D044127:Epigenesis, Genetic; D005260:Female; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D044767:Ubiquitin-Protein Ligases / Q000235:genetics
chemical_list: D020533:Angiogenesis Inhibitors; D047428:Protein Kinase Inhibitors; C111164:BRAP protein, human; D044767:Ubiquitin-Protein Ligases